Works matching AU Hasselbalch, Benedikte

Results: 13

Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.

Published in:

Neuro-Oncology Practice, 2025, v. 12, n. 1, p. 34, doi. 10.1093/nop/npae082

By:

Fougner, Vincent;
Urup, Thomas;
Poulsen, Hans Skovgaard;
Grunnet, Kirsten;
Westmose, Christina Yde;
Melchior, Linea Cecilie;
Larsen, Karen Bonde;
Højgaard, Martin;
Spanggaard, Iben;
Belcaid, Laila;
Rohrberg, Kristoffer Staal;
Lassen, Ulrik;
Hasselbalch, Benedikte;
Nørøxe, Dorte Schou

Publication type:

Article

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

Published in:

Acta Oncologica, 2009, v. 48, n. 1, p. 52, doi. 10.1080/02841860802537924

By:

Poulsen, Hans Skovgaard;
Grunnet, Kirsten;
Sorensen, Morten;
Olsen, Preben;
Hasselbalch, Benedikte;
Nelausen, Knud;
Kosteljanetz, Michael;
Lassen, Ulrik

Publication type:

Article

Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab.

Published in:

Clinical & Translational Oncology, 2025, v. 27, n. 6, p. 2761, doi. 10.1007/s12094-024-03775-z

By:

Jensen, Christina;
Maarup, Simone;
Poulsen, Hans Skovgaard;
Hasselbalch, Benedikte;
Karsdal, Morten;
Svane, Inge Marie;
Lassen, Ulrik;
Willumsen, Nicholas

Publication type:

Article

Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma—A hybrid [18F]FET PET/MRI study.

Published in:

Neuro-Oncology Advances, 2024, v. 6, n. 1, p. 1, doi. 10.1093/noajnl/vdae196

By:

Henriksen, Otto Mølby;
Muhic, Aida;
Lundemann, Michael Juncker;
Larsson, Henrik Bo Wiberg;
Lindberg, Ulrich;
Andersen, Thomas Lund;
Hasselbalch, Benedikte;
Møller, Søren;
Marner, Lisbeth;
Madsen, Karine;
Larsen, Vibeke Andrée;
Poulsen, Hans Skovgaard;
Hansen, Adam Espe;
Law, Ian

Publication type:

Article

Magnetic resonance imaging and o-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

Published in:

Neuro-Oncology Advances, 2024, v. 6, n. 1, p. 1, doi. 10.1093/noajnl/vdae178

By:

Henriksen, Otto Mølby;
Maarup, Simone;
Hasselbalch, Benedikte;
Poulsen, Hans Skovgaard;
Christensen, Ib Jarle;
Madsen, Karine;
Larsen, Vibeke Andrée;
Lassen, Ulrik;
Law, Ian

Publication type:

Article

The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients.

Published in:

Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdad137

By:

Nørøxe, Dorte Schou;
Maarup, Simone;
Fougner, Vincent;
Muhic, Aida;
Møller, Søren;
Urup, Thomas;
Lü, Maya Jeje Schuang;
Weischenfeldt, Joachim;
Hansen, Adam Espe;
Poulsen, Hans Skovgaard;
Lassen, Ulrik;
Hasselbalch, Benedikte

Publication type:

Article

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.

Published in:

Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac157

By:

Benedikte Hasselbalch, Vincent Fougner;
Lassen, Ulrik;
Weischenfeldt, Joachim;
Poulsen, Hans Skovgaard;
Urup, Thomas

Publication type:

Article

Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4677, doi. 10.1007/s00259-022-05917-3

By:

Henriksen, Otto M.;
Hansen, Adam E.;
Muhic, Aida;
Marner, Lisbeth;
Madsen, Karine;
Møller, Søren;
Hasselbalch, Benedikte;
Lundemann, Michael J.;
Scheie, David;
Skjøth-Rasmussen, Jane;
Poulsen, Hans S.;
Larsen, Vibeke A.;
Larsson, Henrik B. W.;
Law, Ian

Publication type:

Article

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

Published in:

APMIS, 2010, v. 118, n. 8, p. 585, doi. 10.1111/j.1600-0463.2010.02631.x

By:

HASSELBALCH, BENEDIKTE;
ERIKSEN, JESPER GRAU;
BROHOLM, HELLE;
CHRISTENSEN, IB JARLE;
GRUNNET, KIRSTEN;
HORSMAN, MICHAEL R.;
POULSEN, HANS SKOVGAARD;
STOCKHAUSEN, MARIE-THÉRÉSE;
LASSEN, ULRIK

Publication type:

Article

Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling.

Published in:

Cancer Investigation, 2010, v. 28, n. 8, p. 775, doi. 10.3109/07357907.2010.483506

By:

Hasselbalch, Benedikte;
Lassen, Ulrik;
Poulsen, Hans S.;
Stockhausen, Marie-Thérése

Publication type:

Article

Severe Skin Lesions in Patients with Glioblastoma Multiforme Treated with a Combination of Cetuximab, Bevacizumab, and Irinotecan.

Published in:

European Journal of Clinical & Medical Oncology, 2010, v. 2, n. 1, p. 1

By:

Sorensen, Morten;
Gaziel, Tine Bernhardtsen;
Hasselbalch, Benedikte;
Skovgaard Poulsen, Hans;
Lassen, Ulrik

Publication type:

Article

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution.

Published in:

Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.597587

By:

Abedi, Armita Armina;
Grunnet, Kirsten;
Christensen, Ib Jarle;
Michaelsen, Signe Regner;
Muhic, Aida;
Møller, Søren;
Hasselbalch, Benedikte;
Poulsen, Hans Skovgaard;
Urup, Thomas

Publication type:

Article

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Published in:

Neuro-Oncology, 2010, v. 12, n. 5, p. 508

By:

Hasselbalch, Benedikte;
Lassen, Ulrik;
Hansen, Steinbjørn;
Holmberg, Mats;
Sørensen, Morten;
Kosteljanetz, Michael;
Broholm, Helle;
Stockhausen, Marie-Thérése;
Poulsen, Hans Skovgaard

Publication type:

Article

Works matching AU Hasselbalch, Benedikte

Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab.

Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma—A hybrid [<sup>18</sup>F]FET PET/MRI study.

Magnetic resonance imaging and o-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients.

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.

Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [<sup>18</sup>F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling.

Severe Skin Lesions in Patients with Glioblastoma Multiforme Treated with a Combination of Cetuximab, Bevacizumab, and Irinotecan.

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution.

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.